血管内皮生长因子-C及其受体-3信号传导在肿瘤发生中的作用
Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis.
作者信息
Vimalraj Selvaraj, Hariprabu Krishnasamy Naidu Gopal, Rahaman Mostafizur, Govindasami Periyasami, Perumal Karthikeyan, Sekaran Saravanan, Ganapathy Dhanraj
机构信息
Department of Applied Mechanics and Biomedical Engineering, Indian Institute of Technology, Madras, Chennai, India.
Centre for Biotechnology, Anna University, Chennai, India.
出版信息
3 Biotech. 2023 Oct;13(10):326. doi: 10.1007/s13205-023-03719-4. Epub 2023 Sep 1.
Abstract
The cancer-promoting ligand vascular endothelial growth factor-C (VEGF-C) activates VEGF receptor-3 (VEGFR-3). The VEGF-C/VEGFR-3 axis is expressed by a range of human tumor cells in addition to lymphatic endothelial cells. Activating the VEGF-C/VEGFR-3 signaling enhances metastasis by promoting lymphangiogenesis and angiogenesis inside and around tumors. Stimulation of VEGF-C/VEGFR-3 signaling promotes tumor metastasis in tumors, such as ovarian, renal, pancreatic, prostate, lung, skin, gastric, colorectal, cervical, leukemia, mesothelioma, Kaposi sarcoma, and endometrial carcinoma. We discuss and update the role of VEGF-C/VEGFR-3 signaling in tumor development and the research is still needed to completely comprehend this multifunctional receptor.
摘要
促癌配体血管内皮生长因子-C（VEGF-C）可激活血管内皮生长因子受体-3（VEGFR-3）。除淋巴管内皮细胞外，一系列人类肿瘤细胞也表达VEGF-C/VEGFR-3轴。激活VEGF-C/VEGFR-3信号传导可通过促进肿瘤内部及周围的淋巴管生成和血管生成来增强转移。刺激VEGF-C/VEGFR-3信号传导可促进卵巢癌、肾癌、胰腺癌、前列腺癌、肺癌、皮肤癌、胃癌、结直肠癌、宫颈癌、白血病、间皮瘤、卡波西肉瘤和子宫内膜癌等肿瘤的转移。我们讨论并更新了VEGF-C/VEGFR-3信号传导在肿瘤发展中的作用，仍需要开展研究以全面理解这一多功能受体。
相似文献
1
Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis.
3 Biotech. 2023 Oct;13(10):326. doi: 10.1007/s13205-023-03719-4. Epub 2023 Sep 1.
2
The role of the VEGF-C/VEGFR-3 axis in cancer progression.
Br J Cancer. 2007 Feb 26;96(4):541-5. doi: 10.1038/sj.bjc.6603487. Epub 2006 Dec 12.
3
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.
4
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
J Biol Chem. 2016 Dec 30;291(53):27265-27278. doi: 10.1074/jbc.M116.736801. Epub 2016 Nov 16.
5
Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
Biomed Pharmacother. 2021 May;137:111331. doi: 10.1016/j.biopha.2021.111331. Epub 2021 Feb 9.
6
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
J Natl Cancer Inst. 2002 Jun 5;94(11):819-25. doi: 10.1093/jnci/94.11.819.
7
Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Clin Cancer Res. 2008 Nov 15;14(22):7205-14. doi: 10.1158/1078-0432.CCR-08-0818.
8
Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Clin Exp Metastasis. 2013 Aug;30(6):819-32. doi: 10.1007/s10585-013-9581-x. Epub 2013 Apr 17.
9
Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Biomed Pharmacother. 2016 Dec;84:660-665. doi: 10.1016/j.biopha.2016.09.083. Epub 2016 Sep 30.
10
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Breast Cancer Res. 2011 Jun 21;13(3):R66. doi: 10.1186/bcr2903.
引用本文的文献
1
Mendelian randomization analysis reveals causal roles of inflammatory cytokines in thyroid cancer pathogenesis.
Discov Oncol. 2025 Sep 2;16(1):1671. doi: 10.1007/s12672-025-03533-9.
2
Exploration of the mechanism of Polyphyllin I against hepatocellular carcinoma based on network pharmacology, molecular docking and experimental validation.
Discov Oncol. 2025 May 28;16(1):941. doi: 10.1007/s12672-025-02341-5.
3
VEGF-C and Lymphatic Vessel Density in Tumor Tissue of Gastric Cancer: Correlations with Pathoclinical Features and Prognosis.
Cancers (Basel). 2025 Apr 23;17(9):1406. doi: 10.3390/cancers17091406.
4
Characterization of hepatocarcinoma cells: lymphatic metastasis potential through enhanced production, expression, and secretion along the VEGF-C/D-VEGFR-3/NRP-2 axis.
Discov Oncol. 2025 Feb 17;16(1):191. doi: 10.1007/s12672-025-01901-z.
5
Case report: Successful therapy with recombinant human vascular endostatin in an elderly man with colon telangiectasia and idiopathic thrombocytopenic purpura.
Front Med (Lausanne). 2025 Jan 15;11:1511513. doi: 10.3389/fmed.2024.1511513. eCollection 2024.
6
Bioinformatics analysis reveals 's prognostic significance in head and neck squamous cell carcinoma and its association with immune cell infiltration.
Transl Cancer Res. 2024 Nov 30;13(11):5953-5970. doi: 10.21037/tcr-24-834. Epub 2024 Nov 27.
7
Structural and dynamical insights revealed the anti-glioblastoma potential of withanolides from Withania coagulans against vascular endothelial growth factor receptor (VEGFR).
J Mol Model. 2024 Oct 24;30(11):383. doi: 10.1007/s00894-024-06178-7.
8
New Interpretations for Sprouting, Intussusception, Ansiform, and Coalescent Types of Angiogenesis.
Int J Mol Sci. 2024 Aug 6;25(16):8575. doi: 10.3390/ijms25168575.
9
ZNF468-mediated epigenetic upregulation of VEGF-C facilitates lymphangiogenesis and lymphatic metastasis in ESCC via PI3K/Akt and ERK1/2 signaling pathways.
Cell Oncol (Dordr). 2024 Oct;47(5):1927-1942. doi: 10.1007/s13402-024-00976-0. Epub 2024 Aug 14.
本文引用的文献
1
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
Int J Mol Sci. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601.
2
Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion.
J Cell Mol Med. 2022 Dec;26(23):5743-5754. doi: 10.1111/jcmm.17571. Epub 2022 Nov 17.
3
PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation.
J Biomed Sci. 2022 Nov 6;29(1):92. doi: 10.1186/s12929-022-00875-2.
4
BANCR positively regulates the HIF-1α/VEGF-C/VEGFR-3 pathway in a hypoxic microenvironment to promote lymphangiogenesis in pancreatic cancer cells.
Oncol Lett. 2022 Oct 11;24(6):422. doi: 10.3892/ol.2022.13542. eCollection 2022 Dec.
5
VEGF receptor heterodimers and homodimers are differentially expressed in neuronal and endothelial cell types.
PLoS One. 2022 Jul 21;17(7):e0269818. doi: 10.1371/journal.pone.0269818. eCollection 2022.
6
Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis.
Front Cardiovasc Med. 2022 Jan 11;8:804934. doi: 10.3389/fcvm.2021.804934. eCollection 2021.
7
VEGFR1 signaling in retinal angiogenesis and microinflammation.
Prog Retin Eye Res. 2021 Sep;84:100954. doi: 10.1016/j.preteyeres.2021.100954. Epub 2021 Feb 25.
8
Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions.
Curr Drug Metab. 2021;22(1):50-59. doi: 10.2174/1389200221666201019143252.
9
The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases.
Cardiovasc Res. 2021 Jul 7;117(8):1877-1890. doi: 10.1093/cvr/cvaa291.
10
The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
Eur J Pharmacol. 2020 Dec 15;889:173641. doi: 10.1016/j.ejphar.2020.173641. Epub 2020 Oct 9.
Zotero 插件